2020 version of the "CSCO primary liver cancer diagnosis and treatment guide" the first-line treatment pattern of the four bright spots.

Turn from . . . Medical Mission Hills recently, the Chinese Society of Clinical Oncology (CSCO) officially announced the high-profile 2020 edition of the "Primary Liver Cancer Diagnosis and Treatment Guide" (hereinafter referred to as the "Guidelines").
in the new edition of the Guide, the first-line treatment pattern of advanced hepatocellular carcinoma (HCC) has changed significantly, with targeted therapy, immunotherapy and combination therapy becoming the main theme, while a number of new drugs from Zeri Pharmaceuticals and Hengrui Pharmaceuticals have attracted much attention.
this article to filter the highlights of the new Edition Guide for readers only.
late-stage HCC first-line treatment recommended highlights one: China's domestic small molecular new drugs recommended I-grade Donovani is the drug independently developed oral multi-target, multikine inhibitor class small molecular anti-tumor drugs, belong to a new class of 1 new drug.
new edition of the Guide lists it as a first-line treatment for advanced hepatocellular carcinoma and is recommended by Class I experts (1A evidence).
it is understood that this is China's domestic small molecule-targeted drugs for the first time to obtain CSCO guidelines HCC first-line treatment I-grade recommendations.
this recommendation is based on the results of a multicenter 2/3 clinical trial called ZGDH3. The zGDH3 study of
, designed and implemented independently by Professor Qin Shuxuan and Professor Bi Feng, included 668 patients with HCC in China, and is one of the largest clinical studies on liver cancer with Chinese sample stake to date.
results showed that Dofenib was able to significantly extend the total life of patients with advanced HCC (12.1 months vs 10.3 months) and had better safety and tolerance than sorafens.
this excellent result represents a major breakthrough in the field of liver cancer treatment of innovative drugs in China.
currently, Donovani has filed a listing application in China for the treatment of patients with hepatocellular carcinoma.
Highlights II: Grade I recommends new atsilizumab and Beva-zhussm monotherapy new version of the Guide to the late-stage HCC first-line treatment also adds another Class I expert recommendation (1A evidence) - atalizumab and bevabead sepsis combined treatment therapy (T-A).
in fact, this combination therapy has previously been NCCN, ESMO and other internationally renowned guidelines as a first-line recommended for liver cancer, and in May this year, the U.S. FDA approved for first-line treatment of liver cell cancer.
atezolizumab, a PD-L1 inhibitor owned by Roche, is an endothelial growth factor (VEGF) inhibitor.
According to a multicenter 3 clinical study called IMbrave 150, 501 subjects were randomly assigned to the T-A programme group and the Sorafenib monodrug treatment group at 2:1 for non-removable HCC patients who had not previously received systemic treatment.
results showed that atalizumab and bevalpzumab immunotherapy improved patientOS (not reached vs 13.2 months), PFS (6.8 months vs 4.3 months) and ORR (27% vs 12%), reducing the risk of death by 42% compared to the standard programme.
positive results provide strong evidence of the benefits of combined immunotherapy in patients with advanced HCC worldwide, including China.
Highlights 3: Hengrui Pharmaceutical PD-1 and Small Molecule Target Drug Double Harvest in the new edition of the Guide, developed by Hengrui Pharmaceuticals PD-1 antibody Carellizhu monotonica and small molecule multi-target anti-angiogenic oral drug apatinib are included.
, o's saliplatin-based system chemotherapy combined with Carelli zuma, and apatinib combined with Carelli zuma, were recommended by advanced HCC first-line treatment level III experts (2B evidence).
noteworthy mention that Carilli Zuma has been approved for liver cancer in China in March this year.
is based on a one-arm, multi-center phase 2 clinical trial led by Professor Qin Shuxuan as the lead researcher (PI), Carelli-Zhu monoto-anti-combination chemotherapy.
study included 34 patients with advanced HCC who had not received systematic treatment and were given the treatment of the Carilli-Bead singular single-drug-based classic chemotherapy regimen.
results showed that the COMBIND confirmed ORR was 26.5%, DCR was 79.4% and the median PFS was 5.5 months.
it is understood that Carilli-Bead singumated combination FOLFOX4 system chemotherapy as a first-line treatment of advanced HCC random, multi-center phase 3 clinical studies are under way.
, according to a 1b study previously published in the Journal of Clinical Oncology, the first-line treatment of advanced hepatocellular carcini in Carilli-zhussa was significant.
, THE ORR was as high as 50%, the median disease-free progression survival (mPFS) reached 7.2 months, and the disease control rate reached 93.8% at 6 weeks.
it is understood that the first-line treatment of advanced hepatocellular carcinoma in the first line of Karili Zhusinga arpanus clinical research has been carried out in the United States, Russia, China and more than 100 countries and regions, more than 100 centers simultaneously.
Highlights IV: Grade III Recommended New Lofatinib Joint Two New PD-1 Antibodies In the New Guide, Eisai's oral multireceptor tyrosine kinase inhibitor Lenvima combined with Paboli zumaor or Navuliu monotophosis obtained a late HCC first-line treatment Class III expert recommendation (2B evidence).
according to data released at this year's ASCO annual meeting, the combined treatment of MsD-1 PD-1 antibody Pabolizumab and ronesterinib achieved a clinically significant total rate of remission for non-removable HCC patients who were not treated with the system.
this is a Phase 1b clinical trial called KEYNOTE-524/study116, with a single arm, showing that combination therapy has an ORR of 36% and a median DOR of 12.6 months. another PD-1 combination therapy
, is also well advanced in first-line treatment for liver cancer.
In a phase 1b clinical study called Study117, the Inc. BMS PD-In-1, according to data published at this year's American Society of Clinical Oncology's Gastrointestinal Oncology Symposium (2020 ASCO GI). 1 Antibody Navuliu syntherapy non-removable HCC, ORR reached 76.7%, DCR was 96.7%, clinical benefit rate (CBR) was 83.3%, and total remission (CR) was 10%.
this also indicates that the lenfarinib combined navuliu monotonica is expected to bring new hope to patients with advanced liver cancer.
hepatocellular carcinoma is a cancer with limited treatment options and a high degree of aggression, and is one of the leading causes of cancer death worldwide.
according to statistics, there are about 370,000 new cases of hepatocellular carcinoma in China every year, and due to the low rate of early screening, about 85% of Chinese patients have missed the best treatment.
median survival of such patients is only about 10 months, with a five-year survival rate of only about 12%.
in recent years, the advent of innovative therapies has brought many new options for patients with advanced liver cancer.
new edition of the Guide incorporates the latest treatments to provide strong medication support for doctors and patients.
we look forward to more breakthroughs in this area that will benefit liver cancer patients."
References, Donafini was included in CSCO's Guidelines for the Diagnosis and Treatment of Primary Liver Cancer and was recommended by Grade I experts. Retrieved Jul 3, 2020, from The Pharmaceutical Seinpharmaceutical Website 2. Retrieved Feb 8, 2020, from Hengrui Pharmaceuticals Official Website , CSCO authoritative guidelines released , China's liver cancer treatment ushered in a new dawn, the epoch-making treatment pattern is coming. Retrieved Jul 20, 2020, from CSCO officer micro-focus on the "drug mingcon" WeChat public number.